# A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Source: https://onco.cc/trials/nct06818643/  
OnCo record `nct06818643` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MK-3120 in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) is a phase 1/2 interventional study registered as NCT06818643 by Merck Sharp & Dohme LLC, with 270 participants planned, started 2025-03-25 and due to reach its primary completion in 2028-10-25. Interventions recorded: MK-3120.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06818643
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06818643: https://clinicaltrials.gov/study/NCT06818643

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06818643.json